NA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The North America lung cancer diagnostics market is projected to register a substantial CAGR of 14.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

Market Segmentation:

North America Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America lung cancer diagnostics market are:

Rise in prevalence and incidence of lung cancer

Increase in healthcare expenditure for better health services

Market Players:

Some of the major players operating in the North America lung cancer diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific Inc.

Abbott

Quest Diagnostics Incorporated

Biodesix

Bio-Rad Laboratories, Inc.

Biocartis

Danaher

DiaSorin S.p.A.

Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)

20/20 Gene Systems

Guardant Health, Inc.

Inivata Ltd.

Vela Diagnostics

LalPathLabs.com

LungLife AI, Inc.

Myriad Genetics, Inc.

NeoGenomics Laboratories

NanoString

Oncocyte Corporation

PerkinElmer Inc.

QIAGEN

Siemens Healthcare GmbH

Veracyte, Inc.

1 INTRODUCTION 52

1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET 52
1.4 LIMITATIONS 54
1.5 MARKETS COVERED 54

2 MARKET SEGMENTATION 57

2.1 MARKETS COVERED 57
2.2 GEOGRAPHICAL SCOPE 58
2.3 YEARS CONSIDERED FOR THE STUDY 59
2.4 CURRENCY AND PRICING 59
2.5 DBMR TRIPOD DATA VALIDATION MODEL 60
2.6 MULTIVARIATE MODELLING 63
2.7 PRODUCT TYPE LIFELINE CURVE 63
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 MARKET TESTING TYPE COVERAGE GRID 68
2.11 VENDOR SHARE ANALYSIS 69
2.12 SECONDARY SOURCES 70
2.13 ASSUMPTIONS 70

3 EXECUTIVE SUMMARY 71

4 PREMIUM INSIGHTS 74

4.1 PORTER'S FIVE FORCES 75
4.2 PESTEL ANALYSIS 76
4.3 INDUSTRY INSIGHTS 77

5 EPIDERMIOLOGY 78

6 REGULATIONS 79

7 MARKET OVERVIEW 82

7.1 DRIVERS 84
- 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 84
- 7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 85
- 7.1.3 INCREASING CASES OF LUNG CANCER 87
- 7.1.4 RISE IN PRODUCT APPROVALS 87
7.2 RESTRAINTS 89
- 7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 89
- 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 89
7.3 OPPORTUNITIES 91
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 91
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 91
- 7.3.3 RISING AWARENESS OF LUNG CANCER 92
7.4 CHALLENGES 93
- 7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 93
- 7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
- 7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94

8 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 95

8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
- 8.2.1 IMAGING INSTRUMENTS 100
  - 8.2.1.1 CT SYSTEMS 100
  - 8.2.1.2 ULTRASOUND SYSTEMS 100
  - 8.2.1.3 MRI SYSTEMS 100
  - 8.2.1.4 OTHERS 100
- 8.2.2 BIOPSY INSTRUMENTS 101
  - 8.2.2.1 NEEDLE BIOPSY 101
  - 8.2.2.2 ENDOSCOPIC BIOPSY 101
  - 8.2.2.3 CORE BIOPSY 101
  - 8.2.2.4 OTHERS 101
- 8.2.3 PATHOLOGY-BASED INSTRUMENTS 102
  - 8.2.3.1 SLIDE STAINING SYSTEMS 102
  - 8.2.3.2 TISSUE PROCESSING SYSTEMS 102
  - 8.2.3.3 CELL PROCESSORS 102
  - 8.2.3.4 PCR INSTRUMENTS 102
  - 8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 102
8.3 CONSUMABLES AND ACCESSORIES 103
- 8.3.1 KITS 104
  - 8.3.1.1 DNA POLYMERASE KITS 104
  - 8.3.1.2 NUCLEIC ACID ISOLATION KITS 104
  - 8.3.1.3 PCR KITS 104
  - 8.3.1.4 OTHERS 104
- 8.3.2 REAGENTS 105
  - 8.3.2.1 ASSAYS 105
  - 8.3.2.2 BUFFERS 105
  - 8.3.2.3 PRIMERS 105
  - 8.3.2.4 OTHERS 105
- 8.3.3 PROBES 106
- 8.3.4 OTHER CONSUMABLES 106

9 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 107

9.1 OVERVIEW 108
9.2 IMAGING TEST 111
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 112
- 9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 112
- 9.2.3 CHEST X-RAY 112
- 9.2.4 BONE SCAN 112
- 9.2.5 MRI 112
- 9.2.6 OTHERS 112
9.3 BIOMARKERS TEST 113
- 9.3.1 EGFR MUTATION TEST 114
- 9.3.2 KRAS MUTATION TEST 114
- 9.3.3 ALK TEST 114
- 9.3.4 HER2 TEST 114
- 9.3.5 OTHERS 115
9.4 BIOPSY 115
- 9.4.1 NEEDLE BIOPSY 116
- 9.4.2 BRONCHOSCOPY BIOPSY 116
- 9.4.3 CORE BIOPSY 116
- 9.4.4 OTHERS 116
9.5 BLOOD TEST 116
- 9.5.1 COMPLETE BLOOD COUNT (CBC) 117
- 9.5.2 BLOOD CHEMISTRY TESTS 117
- 9.5.3 OTHERS 117
9.6 OTHERS 118

10 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119

10.1 OVERVIEW 120
10.2 NON-SMALL CELL LUNG CANCER 123
10.3 SMALL CELL LUNG CANCER 124

11 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER 125

11.1 OVERVIEW 126
11.2 HOSPITAL 129
11.3 ASSOCIATED LABS 129
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 130
11.5 DIAGNOSTIC IMAGING CENTERS 131
11.6 CANCER RESEARCH INSTITUTES 131
11.7 OTHERS 132

12 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 133

12.1 OVERVIEW 134
12.2 DIRECT TENDER 137
12.3 RETAIL SALES 138

13 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY REGION 139

13.1 NORTH AMERICA 140
- 13.1.1 U.S. 149
- 13.1.2 CANADA 154
- 13.1.3 MEXICO 159

14 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 164

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 164

15 SWOT ANALYSIS 165

16 COMPANY PROFILE 166

16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 166
- 16.1.1 COMPANY SNAPSHOT 166
- 16.1.2 REVENUE ANALYSIS 166
- 16.1.3 COMPANY SHARE ANALYSIS 167
- 16.1.4 PRODUCT PORTFOLIO 167
- 16.1.5 RECENT DEVELOPMENTS 167
16.2 THERMO FISHER SCIENTIFIC INC. (2022) 168
- 16.2.1 COMPANY SNAPSHOT 168
- 16.2.2 REVENUE ANALYSIS 168
- 16.2.3 COMPANY SHARE ANALYSIS 169
- 16.2.4 PRODUCT PORTFOLIO 169
- 16.2.5 RECENT DEVELOPMENTS 169
16.3 ABBOTT (2022) 170
- 16.3.1 COMPANY SNAPSHOT 170
- 16.3.2 REVENUE ANALYSIS 170
- 16.3.3 COMPANY SHARE ANALYSIS 171
- 16.3.4 PRODUCT PORTFOLIO 171
- 16.3.5 RECENT DEVELOPMENTS 171
16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 172
- 16.4.1 COMPANY SNAPSHOT 172
- 16.4.2 REVENUE ANALYSIS 172
- 16.4.3 COMPANY SHARE ANALYSIS 173
- 16.4.4 PRODUCT PORTFOLIO 173
- 16.4.5 RECENT DEVELOPMENTS 175
16.5 BIODESIX (2022) 176
- 16.5.1 COMPANY PROFILE 176
- 16.5.2 REVENUE ANALYSIS 176
- 16.5.3 COMPANY SHARE ANALYSIS 177
- 16.5.4 PRODUCT PORTFOLIO 177
- 16.5.5 RECENT DEVELOPMENTS 177
16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 178
- 16.6.1 COMPANY SNAPSHOT 178
- 16.6.2 PRODUCT PORTFOLIO 178
- 16.6.3 RECENT DEVELOPMENTS 178
16.7 BIO-RAD LABORATORIES, INC. (2022) 179
- 16.7.1 COMPANY SNAPSHOT 179
- 16.7.2 REVENUE ANALYSIS 179
- 16.7.3 PRODUCT PORTFOLIO 180
- 16.7.4 RECENT DEVELOPMENTS 180
16.8 BIOCARTIS (2022) 181
- 16.8.1 COMPANY SNAPSHOT 181
- 16.8.2 REVENUE ANALYSIS 181
- 16.8.3 PRODUCT PORTFOLIO 182
- 16.8.4 RECENT DEVELOPMENTS 182
16.9 BODITECH MED INC. 183
- 16.9.1 COMPANY PROFILE 183
- 16.9.2 PRODUCT PORTFOLIO 183
- 16.9.3 RECENT DEVELOPMENTS 183
16.10 DANAHER (2022) 184
- 16.10.1 COMPANY SNAPSHOT 184
- 16.10.2 REVENUE ANALYSIS 184
- 16.10.3 PRODUCT PORTFOLIO 185
- 16.10.4 RECENT DEVELOPMENTS 185
16.11 DIASORIN S.P.A. (2022) 186
- 16.11.1 COMPANY SNAPSHOT 186
- 16.11.2 REVENUE ANALYSIS 186
- 16.11.3 PRODUCT PORTFOLIO 187
- 16.11.4 RECENT DEVELOPMENTS 187
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 188
- 16.12.1 COMPANY SNAPSHOT 188
- 16.12.2 REVENUE ANALYSIS 188
- 16.12.3 PRODUCT PORTFOLIO 189
- 16.12.4 RECENT DEVELOPMENTS 189
16.13 20/20 GENE SYSTEMS 190
- 16.13.1 COMPANY PROFILE 190
- 16.13.2 PRODUCT PORTFOLIO 190
- 16.13.3 RECENT DEVELOPMENTS 190
16.14 GUARDANT HEALTH INC. 191
- 16.14.1 COMPANY PROFILE 191
- 16.14.2 PRODUCT PORTFOLIO 191
- 16.14.3 RECENT DEVELOPMENTS 191
16.15 INIVATA LTD. 192
- 16.15.1 COMPANY PROFILE 192
- 16.15.2 PRODUCT PORTFOLIO 192
- 16.15.3 RECENT DEVELOPMENTS 192
16.16 LALPATHLABS.COM (2022) 193
- 16.16.1 COMPANY SNAPSHOT 193
- 16.16.2 REVENUE ANALYSIS 193
- 16.16.3 PRODUCT PORTFOLIO 194
- 16.16.4 RECENT DEVELOPMENTS 195
16.17 LUNGLIFE AI, INC. (2022) 196
- 16.17.1 COMPANY SNAPSHOT 196
- 16.17.2 PRODUCT PORTFOLIO 196
- 16.17.3 RECENT DEVELOPMENTS 196
16.18 MEDGENOME 197
- 16.18.1 COMPANY SNAPSHOT 197
- 16.18.2 PRODUCT PORTFOLIO 197
- 16.18.3 RECENT DEVELOPMENTS 198
16.19 MYRIAD GENETICS, INC. 199
- 16.19.1 COMPANY SNAPSHOT 199
- 16.19.2 PRODUCT PORTFOLIO 199
- 16.19.3 RECENT DEVELOPMENTS 199
16.20 NEOGENOMICS LABORATORIES (2022) 200
- 16.20.1 COMPANY SNAPSHOT 200
- 16.20.2 REVENUE ANALYSIS 200
- 16.20.3 PRODUCT PORTFOLIO 201
- 16.20.4 RECENT DEVELOPMENTS 201
16.21 NANOSTRING (2022) 202
- 16.21.1 COMPANY SNAPSHOT 202
- 16.21.2 REVENUE ANALYSIS 202
- 16.21.3 PRODUCT PORTFOLIO 203
- 16.21.4 RECENT DEVELOPMENTS 203
16.22 NANOENTEK 204
- 16.22.1 COMPANY PROFILE 204
- 16.22.2 PRODUCT PORTFOLIO 204
- 16.22.3 RECENT DEVELOPMENTS 204
16.23 ONCOCYTE CORPORATION 205
- 16.23.1 COMPANY PROFILE 205
- 16.23.2 SERVICE PORTFOLIO 205
- 16.23.3 RECENT DEVELOPMENTS 205
16.24 PERKINELMER INC 206
- 16.24.1 COMPANY PROFILE 206
- 16.24.2 REVENUE ANALYSIS 206
- 16.24.3 PRODUCT PORTFOLIO 207
- 16.24.4 RECENT DEVELOPMENTS 207
16.25 PLEXBIO 208
- 16.25.1 COMPANY SNAPSHOT 208
- 16.25.2 PRODUCT PORTFOLIO 208
- 16.25.3 RECENT DEVELOPMENTS 208
16.26 QIAGEN 209
- 16.26.1 COMPANY SNAPSHOT 209
- 16.26.2 REVENUE ANALYSIS 209
- 16.26.3 PRODUCT PORTFOLIO 210
- 16.26.4 RECENT DEVELOPMENTS 210

16.27 SIEMENS HEALTHCARE GMBH 211
- 16.27.1 COMPANY SNAPSHOT 211
- 16.27.2 REVENUE ANALYSIS 211
- 16.27.3 PRODUCT PORTFOLIO 212
- 16.27.4 RECENT DEVELOPMENTS 212
16.28 VERACYTE, INC. (2022) 213
- 16.28.1 COMPANY SNAPSHOT 213
- 16.28.2 REVENUE ANALYSIS 213
- 16.28.3 PRODUCT PORTFOLIO 214
- 16.28.4 RECENT DEVELOPMENTS 214
16.29 VELA DIAGNOSTICS 215
- 16.29.1 COMPANY PROFILE 215
- 16.29.2 PRODUCT PORTFOLIO 215
- 16.29.3 RECENT DEVELOPMENTS 217

17 QUESTIONNAIRE 218

18 RELATED REPORTS 221

LIST OF FIGURES

FIGURE 1 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 23
FIGURE 2 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 26
FIGURE 3 NORTH AMERICA LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 27
FIGURE 4 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 28
FIGURE 5 NORTH AMERICA LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 28
FIGURE 6 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 31
FIGURE 7 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 32
FIGURE 8 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 34
FIGURE 9 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 35
FIGURE 10 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 39
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD 40
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030 40
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET 49
FIGURE 14 THE NORTH AMERICA MORTALITY RATE DUE TO CANCER 52
FIGURE 15 THE DATA GIVEN BELOW SHOWS THE INCREASING NORTH AMERICA CANCER RATE IN 2020 52
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT 55
FIGURE 17 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 62
FIGURE 18 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 63
FIGURE 19 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 63
FIGURE 20 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 64
FIGURE 21 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 74
FIGURE 22 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 75
FIGURE 23 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 75
FIGURE 24 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 76
FIGURE 25 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 86
FIGURE 26 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 87
FIGURE 27 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 87
FIGURE 28 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 88
FIGURE 29 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022 92
FIGURE 30 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 93
FIGURE 31 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 93
FIGURE 32 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 94
FIGURE 33 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 100
FIGURE 34 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 101
FIGURE 35 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 101
FIGURE 36 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 102
FIGURE 37 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 107
FIGURE 38 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 108
FIGURE 39 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 108
FIGURE 40 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 109
FIGURE 41 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 109
FIGURE 42 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 130